A Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma

Inclusion Criteria:

- Subject must have histologically documented diagnosis of non-Hodgkin's lymphoma as
defined by a B-cell neoplasm in the World Health Organization classification scheme
except as noted in exclusion criteria.

- Subject (non-diffuse large B-cell lymphoma) must have relapsed or refractory
non-Hodgkin's lymphoma, and require treatment in the opinion of the investigator.

- Subject with diffuse large B-cell lymphoma must have relapsed diffuse large B-cell
lymphoma or must have progressed after salvage therapy (with or without standard
chemotherapy) for diffuse large B-cell lymphoma. The subject must have received first
line therapy with Rituximab-Cyclophosphamide, Hydroxydaunomycin, Vincristine
(Oncovin), Prednisone (R-CHOP) [or a similar standard rituximab-containing front-line
chemoimmunotherapy regimen including, but not limited to Etoposide, Prednisone,
Vincristine (Oncovin), Cyclophosphamide, Doxorubicin (Hydrochloride) + Rituximab
(EPOCH + R); Rituximab, Cyclophosphamide, Etoposide, Procarbazine, Prednisone (RCEPP);
Rituximab, Cyclophosphamide, Mitoxantrone (Novantrone), Vincristine (Oncovin),
Prednisone (RCNOP); Dose-adjusted-Etoposide, Prednisone, Vincristine(Oncovin),
Cyclophosphamide, Doxorubicin (Hydrocloride) (DA-EPOCH); and Rituximab,
Cyclophosphamide, Etoposide, Vincristine (Oncovin), Prednisone (RCEOP)].

- Subject must have adequate coagulation, renal, and hepatic function, per laboratory
reference range at Screening.

Exclusion Criteria:

- Subject has been diagnosed with Post-Transplant Lymphoproliferative Disease, Burkitt's
lymphoma, Burkitt-like lymphoma, lymphoblastic lymphoma/leukemia, chronic lymphocytic
leukemia, small lymphocytic lymphoma or mantle cell lymphoma (MCL).

- Subject has refractory diffuse large B-cell lymphoma, defined as meeting any of the
following criteria:

- Subject progressed during or within 3 months of completion of a planned course of
first-line therapy with Rituximab-Cyclophosphamide, Hydroxydaunomycin,
Vincristine (Oncovin), Prednisone (R-CHOP) or an equivalent regimen;

- Subject had no response (i.e., stable disease only) to first-line therapy with
R-Cyclophosphamide, Hydroxydaunomycin, Vincristine (Oncovin), Prednisone (R-CHOP)
or an equivalent regimen;

- Subject progressed during or within 2 months of completion of their last planned
course of salvage therapy with chemotherapy (with or without rituximab, may
include autologous stem cell transplant).

- Subject has tested positive for human immunodeficiency virus (HIV).

- Subject has a cardiovascular disability status of New York Heart Association Class
greater or equal to 2. Class 2 is defined as cardiac disease in which patients are
comfortable at rest but ordinary physical activity, results in fatigue, palpitations,
dyspnea or anginal pain.

- Subject has a significant history of renal, neurologic, psychiatric, endocrinologic,
metabolic, immunologic, or hepatic disease that in the opinion of the Investigator
would adversely affect his/her participating in this study.